EU approves rights to genetic material

Steady the course: property rights in genetic material.

A Genetic-DEA Approach to Reveal Property Rights Priorities

FDA approves new drug to treat dementia.

Actavis and Adamas Pharmaceuticals, Inc., announced that the U.S. Food and Drug Administration has approved the New Drug Application for NamzaricTM for the treatment of moderate to severe dementia of the Alzheimer’s type in patients stabilized on memantine hydrochloride and donepezil hydrochloride. Namzaric will be available in two dosage strengths: 28/10 mg (memantine extended release/donepezi...

Assessing Parental Rights for Children with Genetic Material from Three Parents

Rights, privacy, and genetic screening.

A very interesting dialogue has been established here concerning the role of insurance in our society. I would, however, like to step back from the insurance issue to discuss several major developments that will shape how genetic information is used in our society. First, revolutionary change is going on among employers in the way they respond to the cost of health insurance. Employers are sayi...